



5610

2/18/02

Please type a plus sign (+) inside this box → ☐

635 Rec'd PCT/PTC 08 JUL 2002

PCT

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application	10/018,386
	Filing Date	December 13, 2001
	First Named	FREIDRICH, Gabi
	Group Art Unit	n/a
	Examiner Name	n/a
Total Number of Pages in This Submission	Attorney Docket Number	MSB-7268-PCT-US

RECEIVED

JUL 9 2002

TECH CENTER 1600/2300

ENCLOSURES <i>(check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Post Card
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Includes copies of all references listed on 1449.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	John W. Mahoney Attorney for Applicants Reg. No. 44, 892
Signature	<i>John W. Mahoney</i>
Date	6-28-02

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: <u>7-1-2002</u>	
Typed or printed name	Luajuana LeGrande
Signature	<i>Luajuana LeGrande</i>
Date	July 1, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED

JUL 31 2002

TECH CENTER 1600/2000

In Re Application of: Freidrich, et al.

Group Art Unit: N.A.

Serial Number: 10/018,386

Examiner: N.A.

Filed: 12/13/01

Title: Methods for Modulating Angiogenesis by Using the Anti-Angiogenic  
Angiotensin-7 and Polynucleotides encoding therefor.

*P#7*

**Information Disclosure Statement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In order to comply with the discretionary regulations 37 CFR 1.97 and 1.98, attached hereto is Form PTO-1449, and copies of the documents listed thereon pursuant to 37 CFR 1.97. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited be given thorough consideration and that it be cited in the record of the prosecution history.

No representation is intended that the documents represent the results of a complete search. It is anticipated that the Examiner, in the normal course of examination, will make an independent search and determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b), and in the course of each search, will review for relevance each document cited in the attached form.

Respectfully Submitted,

*John W. Mahoney*

John W. Mahoney  
Reg. No. 44,892

Date: 6/28/02

Bayer Corporation  
P.O. Box 1986  
800 Dwight Way  
Berkeley, California 94701-1986  
(510) 705-7725

—

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	10/018,386
<b>Filing Date</b>	12-13-2001
<b>First Named Inventor</b>	FRIEDRICH, Gabi
<b>Group Art Unit</b>	N/A
<b>Examiner Name</b>	N/A
<b>Attorney Docket Number</b>	MSB-7268-PCT-US

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Attorney Docket Number	MSB-7268-PCT-US
------------------------	-----------------

RECEIVED

2002

TECH CENTER 1600/2300

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

OIPE  
 JUL 08 2002  
 T & TRADEMARK DE  
 Ex

+

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	10/018,386
<b>Filing Date</b>	12-13-2001
<b>First Named Inventor</b>	FRIEDRICH, Gabi
<b>Group Art Unit</b>	N/A
<b>Examiner Name</b>	N/A
<b>Attorney Docket Number</b>	MSB-7268-PCT-US

*(use as many sheets as necessary)*

Page	2	of	2
------	---	----	---

Attorney Docket Number	MSB-7268-PCT-US
------------------------	-----------------

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	-----------------------	---

T2

MAISONPIERRE, et al., Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family, *Oncogene* 1993, vol 8, pages 1631-1637.

KORHONEN, et al., Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization, *Blood*, vol. 80, No. 10 (November 15), 1992, pages 2548-2555.

VALENZUELA, et al, Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans, Proc. Natl. Acad. Sci. USA, vol 96, March 1999, pages 1904-1909.

PARTANEN, et al., Putative tyrosine kinases expressed in K-562 human leukemia cells, Proc. Natl. Acad. Sci. USA, vol 87, November 1990, Cell Biology, pages 8913-8917.

RECEIVED

JUL 31 2002

TECH CENTER 1600/2300

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.